The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials
2012 ◽
Vol 4
(5)
◽
pp. 849-858
◽
2013 ◽
Vol 2
(1)
◽
pp. 146-150
◽
2014 ◽
Vol 15
(14)
◽
pp. 5691-5696
◽
2020 ◽
Vol 2020
◽
pp. 1-20